BioMech, ēlizur Announce Partnership Integrating AI-enabled Motion Analytics into Physical Therapy Solution

BioMech Health, a division of BioMech Holdings, LLC, and ēlizur, a leading musculoskeletal solutions provider, announced today a groundbreaking agreement to integrate BioMech Lab™ Into the Shoulder Strengthening and Stabilization System (SSS).

The national partnership brings together two industry leading mechanical and digital solutions to create an in-home product capable of quantifying rehabilitative outcomes while increasing patient adherence to and engagement with physician-directed physical therapy protocols.

“Coupling the SSS advanced mechanical technology and BioMech Lab’s cutting-edge motion analytics is the perfect union to deliver enhanced therapeutic decision support for improved patient compliance with prescribed physical therapy protocols. It also provides the quantifiable outcomes needed to confirm the reliability of the SSS device,” said BioMech Founder Frank Fornari, Ph.D.

BioMech Lab™ delivers to clinicians the real-time functional motion metrics needed to rapidly evaluate, design, and monitor physical, surgical, pharmaco, and cognitive therapies. Using advanced sensor technology, powerful artificial intelligence (AI) and machine learning (ML) algorithms, and interactive biofeedback, BioMech Lab captures motion data in clinical and real-world settings and delivers precise, accurate, and reproducible assessments and treatment modifications that stratify risk and improve care outcomes.

“SSS has helped more than 4,000 patients accelerate rehabilitation from injury or surgery while reducing the number of required outpatient sessions. Adding BioMech Lab’s powerful analytics and biofeedback capabilities creates an even more robust system that can now deliver the actionable information needed to maximize outcomes while lowering costs,” said ēlizur President Jim Grant.

The SSS is designed for early-stage in-home rehabilitation use in the interim between discharge and outpatient therapy. A complement to outpatient rehabilitation, SSS offers a convenient, cost-effective alternative for patients who are not yet ready for, or do not have easy access to outpatient rehabilitation centers. ēlizur virtual clinical specialists – physical therapists, athletic trainers and orthopedic nurses depending upon the patient’s specific need – support the patient with set up and compliant use of the SSS device based on the physician-prescribed therapeutic protocol.

Says Fornari: “The BioMech Lab-SSS combination leverages automation to transform an integral but subjective assessment process and delivers quantifiable metrics to measure progress and validate effectiveness of therapeutic protocols.”

SourceBioMech

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”